Meridian Bioscience Comments on Recent FDA Press Statement
CINCINNATI, July 13, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO). Meridian Bioscience, Inc. is providing the following comments regarding the FDA press statement and website announcement concerning the posting of the Form FDA-483 issued following the inspection of Magellan Diagnostics, which closed on June 29, 2017. As FDA noted, this Form represents the investigators’ observations […]